Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux

Summary

Edoxaban, an oral direct factor Xa (FXa) inhibitor, is in phase III clinical development for stroke prevention in atrial fibrillation and treatment of venous thromboembolism. The shed blood model allows for study of activated coagulation at a site of standardised tissue injury due to local release of tissue factor. The objective of this study was to evaluate the effect of three doses of edoxaban on markers of coagulation in shed and venous blood versus placebo and a standard prophylactic dose of fondaparinux. A total of 100 healthy male subjects were randomised to receive single doses of one of five treatments: subcutaneously administered fondaparinux 2.5 mg; orally administered edoxaban 30, 60, or 120 mg; or placebo. The primary objective was measurement of blood coagulation markers prothrombin fragment 1+2 (F₁₊₂) and thrombinantithrombin (TAT) complex, and platelet activation marker β-thromboglobulin (β-TG), in venous and shed blood. Secondary objectives included pharmacokinetics, shed blood volume, and safety of edoxaban. Single doses of edoxaban caused rapid and significant decreases of F₁₊₂, TAT, and β-TG in the shed blood model, indicating inhibition of thrombin generation and platelet activation. Inhibition was significantly less for fondaparinux versus edoxaban. Baseline-corrected F₁₊₂, TAT, and β-TG values demonstrated sustained inhibition up to 24 hours for shed blood in the edoxaban groups but no significant inhibition in venous blood. Overall, edoxaban treatments were well tolerated. In conclusion, single oral doses of edoxaban 30, 60, or 120 mg caused rapid and sustained inhibition of coagulation up to 24 hours in the shed blood model.

Keywords

Coagulation markers - direct factor Xa inhibitor - edoxaban - fondaparinux - shed blood model

• References

• 1 Rai R, Sprengeler PA, Elrod KC. et al. Perspectives on factor Xa inhibition. Curr Med Chem 2001; 8: 101-119.
• 2 Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48: 1-22.
• 3 Rezaie AR. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost 2003; 89: 112-121.
• 4 Kunitada S, Nagahara T, Hara T. Inhibitors of factor Xa. In: Antithrombotics (Handbook of Experimental Pharmacology). Vol 132. Berlin, Germany: Springer; 1998. pp. 397-420.
• 5 Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2007; 29: 155-165.
• 6 Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 2001; 97: 2308-2313.
• 7 Karnicki K, McBane RD, Miller RS. et al. Inhibition and reversal of platelet-rich arterial thrombus in vivo: direct vs. indirect factor Xa inhibition. J Thromb Haemost 2004; 2: 2162-2169.
• 8 Arixtra [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009
• 9 Walenga JM, Jeske WP, Samama MM. et al. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs 2002; 11: 397-407.
• 10 Parody R, Oliver A, Souto JC. et al. Fondaparinux (Arixtra^→), as an alternative antithrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica 2003; 88: e147-148.
• 11 Boneu B, Necciari J, Cariou R. et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74: 1468-1473.
• 12 Ogata K, Mendell-Harary J, Tachibana M. et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50: 743-753.
• 13 Weitz JI, Connolly SJ, Patel I. et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; 104: 633-641.
• 14 Raskob G, Cohen AT, Eriksson BI. et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010; 104: 642-649.
• 15 Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010; 8: 2458-2468.
• 16 Weiss HJ, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988; 71: 629-635.
• 17 Sarich TC, Eriksson UG, Mattsson C. et al. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost 2002; 87: 300-305.
• 18 Wolzt M, Eder M, Weltermann A. et al. Comparison of the effects of different low molecular weight heparins on the hemostatic system activation in vivo in man. Thromb Haemost 1997; 78: 876-879.
• 19 Eichinger S, Wolzt M, Schneider B. et al. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Arterioscler Thromb Vasc Biol 1995; 15: 886-892.
• 20 Szczeklik A, Musial J, Undas A. et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholest -erolemia. J Am Coll Cardiol 1999; 33: 1286-1293.
• 21 Wolzt M, Weltermann A, Nieszpaur-Los M. et al. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb Haemost 1995; 73: 439-443.
• 22 Wolzt M, Levi M, Sarich TC. et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost 2004; 91: 1090-1096.
• 23 Rand MD, Lock JB, van’t Veer C. et al. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-3445.
• 24 Sarich TC, Wolzt M, Eriksson UG. et al. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol 2003; 41: 557-564.
• 25 Thorngren M, Shafi S, Born GV. Thromboxane A2 in skin-bleeding-time blood and in clotted venous blood before and after administration of acetylsalicylic acid. Lancet 1983; 1: 1075-1078.
• 26 Depasse F, Gerotziafas GT, Busson J. et al. Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparin -ux (Arixtra) anti-Xa activity. J Thromb Haemost. 2004; 2: 346-348.
• 27 Samama MM, Amiral J, Guinet C. et al. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma [letter]. Thromb Haemost 2010; 104: 1078-1079.